The Priority Review

Tag

Dapagliflozin

1 story

  1. Clinical trials

    Eli Lilly posts results of Phase 3 orforglipron vs dapagliflozin study

    The company posted results for the ACHIEVE-2 study, a Phase 3, randomized, open-label trial that enrolled 962 participants with type 2 diabetes. The study compared once-daily oral orforglipron (LY3502970) with dapagliflozin and completed primary data collection on September 26, 2025.